What is a targeted therapy? The view of the biologist;Qu'est-ce qu'une thérapeutique ciblée? Le point de vue du biologiste

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Robert, Jacques ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Chemotherapy; Oncogenesis; Patient selection; Targeted therapies

Indexed keywords

ANGIOGENESIS; BIOLOGY; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL CYCLE; CELL IMMORTALIZATION; CELL PROLIFERATION; COMPREHENSION; DRUG DESIGN; GENETICS; HISTORY; METASTASIS; MOLECULAR BIOLOGY; MOLECULE; ONCOLOGY; PATIENT SELECTION; PHYSICIAN; PRESCRIPTION; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL CYCLE; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 36248958175     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0434     Document Type: Review

References (32)

1. Weinstein JN, Myers TJ, O'Connor PM, et al. NCI database: an information-intensive approach to the molecular pharmacology of cancer. Science 1997 ; 275 : 343-9.
2. Powis G. Signalling pathways as targets for anticancer drug development. Pharmacol Ther 1994 ; 62 : 57-95.
3. Stehelin D, Varmus HE, Bishop JM, Vogt PK. DNA related to the transforming gene (s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976 ; 260 : 170-3.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 ; 100 : 57-70.
5. Heidelberger C. On the rational development of a new drug : the example of the fluorinated pyrimidines. Cancer Treat Rep 1981 ; 65(Suppl 3) : 3-9.
6. Blay JY. Targeted therapies of cancer : not lost in translation. Bull Cancer 2006 ; 93 : 799-804.
7. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999 ; 96 : 4325-9.
8. Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci USA 2001 ; 98 : 8092-7.
9. Mills GB. Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics : inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001 ; 98 : 10031-3.
10. Weinberg RA. Oncogenes, anticoncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989 ; 49 : 3713-21.
11. Felsher DW. Cancer revoked : oncogenes as therapeutic targets. Nat Rev Cancer 2003 ; 3 : 375-80.
12. Weinstein IB. Disorders in cell circuitry during multistage carcinogenesis : the role of homeostasis. Carcinogenesis 2000 ; 21 : 857-64.
13. Weinstein IB. Addiction to oncogenes : the Achilles heal of cancer. Science 2002 ; 297 : 63-4.
14. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002 ; 297 : 102-4.
15. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffertz S, Herlyn M. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 1999 ; 59 : 4876-81.
16. Chin L, Tamn A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic RAS in tumour maintenance. Nature 1999 ; 400 : 468-72.
17. Haber D, Harlow E. Tumour-suppressor genes : evolving definitions in the genomic age. Nat Genet 1997 ; 16 : 320-2.
18. Neidle S, Thurston DE. Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer 2005 ; 5 : 285-96.
19. Vidal M, Gigoux V, Garbay C. SH2 and SH3 domains as targets for anti-proliferative agents. Crit Rev Oncol Hematol 2001 ; 40 : 175-86.
20. Bennasroune A, Fickova M, Gardin A, Dirrig-Grosch S, Aunis D, Cremel G, et al. Transmembrane peptides as inhibitors of ErbB receptor signaling. Mol Biol Cell 2004 ; 15 : 3464-74.
21. Barnard D, Sun H, Baker L, Marshall MS. In vitro inhibition of Ras-Raf association by short peptides. Biochem Biophys Res Commun 1998 ; 247 : 176-80.
22. Hélène C. Control of oncogene expression by antisense nucleic acids. Eur J Cancer 1994 ; 30A : 1721-6.
23. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Heller C, Lucas T, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000 ; 356 : 1728-33.
24. Dias N, Stein CA. Antisense oligonucleotides : Basic concepts and mechanisms. Mol Cancer Ther 2002 ; 1 : 347-55.
25. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotides RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 ; 411 : 494-8.
26. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 2002 ; 99 : 1443-8.
27. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002 ; 2 : 243-7.
28. Wright L, Kearney P. Current status of ribozymes as gene therapy agents for cancer. Cancer Invest 2001 ; 19 : 495-509.
29. Cerchia L, Hamm J, Libri D, Tavitian B, De Francisas V. Nucleic acid aptamers in cancer medicine. FEBS Lett 2002 ; 528 : 12-6.
30. Ruckman J, Green LS, Beeson J, Waugh S, Gillette WL, Henninger DD, et al. 2′-fluoropyrimidine RNA-based aptamers to the 165-aminoacid form of vasculo-endothelial growth factor (VEGF). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998 ; 273 : 20556-67.
31. Workman P. Challenges in PK/PD measurements in modern drug development. Eur J Cancer 2002 ; 38 : 2189-93.
32. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology 2003 ; 17(Suppl 12) : 23-8.